# Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

> **NCT02301130** · PHASE1 · COMPLETED · sponsor: **Kyowa Kirin, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** mogamulizumab
- **BIOLOGICAL:** MEDI4736 (Durvalumab)
- **BIOLOGICAL:** tremelimumab

## Key facts

- **NCT ID:** NCT02301130
- **Lead sponsor:** Kyowa Kirin, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-26
- **Primary completion:** 2017-12-08
- **Final completion:** 2018-03-05
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02301130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02301130, "Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02301130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*